Abstract Number: PB0006
Meeting: ISTH 2021 Congress
Background: Platelet-derived microparticles (PMPs) measured by flowcytometry (FCM) have proved recently to be an important pro coagulant element along the pathogenesis and the therapeutic challenge of ischemic heart disease (IHD), especially the acute coronary syndrome (ACS). Therapeutic Program of which includes either a single or a more effective dual anti-platelet therapy (DAPT), with wide range of variability among patients’ response, whereas an old-modality partially-subjective platelet function assay, namely light transmission aggregometry (LTA) were used to monitor such response.
Aims: To evaluate the FCM-PMPs role in monitoring the response of DAPT therapy of ACS, in comparison to single anti platelet therapy among Egyptian patients of ischemic heart disease.
Methods: One hundred and thirty individuals, divided as 100 Egyptian patients with proven IHD presented to Ain Shams university hospital- CCU (of which included 68 ACS patients), and 30 age- and sex- matched controls. None had active inflammatory condition causing platelet activation. They all had consent, history taking, especially for their anti-platelet drug intake (single/ DAPT). They also had physical examination and Flowcytometric assay for PMPs in their 3.2% citrated platelet-free plasma samples, standardized with Magamix beads, expressed in both terms of % of activation and number/microlitre.
Results: On comparing the citrated-plasma PMPs’ measurements, as regards the % of activation and number/microlitre, among patients treated with single anti-platelet and those with DAPT, using a Mann-Whitney test of significance, all results were statistically significant.
Conclusions: Flowcytometric PMPs analysis in citrated platelet-free plasma is a promising indicator assay in monitoring IHD (especially ACS) therapeutic response, and aiding in dose escalation, especially when DAPT is adopted. Moreover, they could efficiently replace LTA.
To cite this abstract in AMA style:Farouqe N, Wahba M, Saad A, El-Gamal R, Elsakhawy Y, Farouk M. Flowcytometric Assay of Platelet-derived Microparticles and the Dual Anti-platelet Therapy in Egyptian Patients with Ischemic Heart Disease, a Promising Indicator [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/flowcytometric-assay-of-platelet-derived-microparticles-and-the-dual-anti-platelet-therapy-in-egyptian-patients-with-ischemic-heart-disease-a-promising-indicator/. Accessed September 21, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/flowcytometric-assay-of-platelet-derived-microparticles-and-the-dual-anti-platelet-therapy-in-egyptian-patients-with-ischemic-heart-disease-a-promising-indicator/